Finance

Lists
2096:HKG
Simcere Pharmaceutical Group Ltd
HK$11,02
+1,75%
(+0,19) 1D
16 Okt., 16:08:14 GMT+8  ·   HKD
All symbols
SymbolPriceChange% Change
Generating top insights for 2096...
Open
HK$10,85
High
HK$11,29
Low
HK$10,85
Mkt. cap
28,30 mjd
Avg. vol.
4,02 m
Volume
5,80 m
Dividend
1,88%
Quarterly dividend
HK$0,05
Ex-dividend date
18 Jun. 2025
P/E ratio
16,54
52-wk high
HK$14,38
52-wk low
HK$9,07
EPS
HK$0,67
Shares outstanding
2,57 mjd
No. of employees
7 k
Open
HK$10,85
High
HK$11,29
Low
HK$10,85
Mkt. cap
28,30 mjd
Avg. vol.
4,02 m
Volume
5,80 m
Dividend
1,88%
Quarterly dividend
HK$0,05
Ex-dividend date
18 Jun. 2025
P/E ratio
16,54
52-wk high
HK$14,38
52-wk low
HK$9,07
EPS
HK$0,67
Shares outstanding
2,57 mjd
No. of employees
7 k
News stories
From web sources and news partners
Profile
Simcere Pharmaceutical Group or Simcere Pharmaceutical is a manufacturer and supplier of branded generic pharmaceuticals in the Chinese market. Its focus is to introduce generic and pharmaceutical products for the treatment of diseases with high incidence and/or mortality rate. The company has introduced a generic anti-stroke medication under the brand name, Bicun, and an anti-cancer medication under the brand name, Endu. Its products include antibiotics, anti-stroke medications, anti-inflammatory drugs, anti-cancer medications and other medicines. In addition, it has obtained approvals from the China State Food and Drug Administration to manufacture and sell over 210 other products. Wikipedia
About Simcere Pharmaceutical Group Ltd
CEORen Jinsheng
Employees7,06 k
Founded1995
HeadquartersNanjing, Jiangsu, Sjina
SectorPharmaceutical industry
Previous reports
Loading Previous Earnings...
Revenue
Net income
All values in CNY
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
2,07 mjd
2,07 mjd
2,29 mjd
2,29 mjd
Cost of goods sold
365,25 m
365,25 m
382,55 m
382,55 m
Cost of revenue
365,25 m
365,25 m
382,55 m
382,55 m
Research and development expenses
465,30 m
465,30 m
412,46 m
412,46 m
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
949,52 m
949,52 m
1,01 mjd
1,01 mjd
Operating expense
1,36 mjd
1,36 mjd
1,39 mjd
1,39 mjd
Total operating expenses
1,72 mjd
1,72 mjd
1,77 mjd
1,77 mjd
Operating income
351,33 m
351,33 m
520,99 m
520,99 m
Other non operating income
-
-
-
-
EBT including unusual items
425,92 m
425,92 m
483,36 m
483,36 m
EBT excluding unusual items
348,89 m
348,89 m
531,61 m
531,61 m
Income tax expense
55,72 m
55,72 m
70,09 m
70,09 m
Effective tax rate
13,08%
13,08%
14,50%
14,50%
Other operating expenses
-56,27 m
-56,27 m
-42,94 m
-42,94 m
Net income
370,20 m
370,20 m
414,36 m
414,36 m
Net profit margin
17,86%
17,86%
18,09%
18,09%
Earnings per share
-
-
-
-
Interest and investment income
14,60 m
14,60 m
24,20 m
24,20 m
Interest expense
-23,63 m
-23,63 m
-24,61 m
-24,61 m
Net interest expenses
-9,03 m
-9,03 m
-416,00 k
-416,00 k
Depreciation and amortization charges
-
-
-
-
EBITDA
449,72 m
449,72 m
606,04 m
606,04 m
Gain or loss from assets sale
-115,50 k
-115,50 k
-
-
AI content may include mistakes. Learn more
Google-programme